Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

Blood Adv (2025) 9 (7): 1644–1657.

https://doi.org/10.1182/bloodadvances.2024015157

Published: 2025

Includes: Supplemental data

Journal Articles

Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis

Peter A. Riedell, Connor B. Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T. Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J. Schuster, Andy I. Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P. McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter

Blood Adv (2025) 9 (5): 1232–1241.

https://doi.org/10.1182/bloodadvances.2024014164

Published: 2025

Includes: Supplemental data

Journal Articles

Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes

Blood Adv (2024) 9 (1): 151–161.

https://doi.org/10.1182/bloodadvances.2024014555

Published: 2024

Includes: Supplemental data

Journal Articles

Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity

Blood Adv (2024) 8 (21): 5603–5611.

https://doi.org/10.1182/bloodadvances.2024013636

Published: 2024

Includes: Supplemental data

Journal Articles

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Nausheen Ahmed, William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Jamie Brower, Gunjan L. Shah, Andy I. Chen, Olalekan O. Oluwole, Stephen J. Schuster, Michael R. Bishop, Joseph P. McGuirk, Peter A. Riedell

Blood Adv (2024) 8 (20): 5346–5354.

https://doi.org/10.1182/bloodadvances.2023012549

Published: 2024

Includes: Supplemental data

Journal Articles

CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas

Blood Adv (2024) 8 (19): 5192–5199.

https://doi.org/10.1182/bloodadvances.2024013393

Published: 2024

Includes: Supplemental data

Journal Articles

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Tania Jain, Noel Estrada-Merly, M. Queralt Salas, Soyoung Kim, Jakob DeVos, Min Chen, Xi Fang, Rajat Kumar, Marcio Andrade-Campos, Hany Elmariah, Vaibhav Agrawal, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Karen Ballen, Amer Beitinjaneh, Vijaya Raj Bhatt, Christopher Bredeson, Zachariah DeFilipp, Bhagirathbhai Dholaria, Nosha Farhadfar, Shatha Farhan, Arpita P. Gandhi, Siddhartha Ganguly, Usama Gergis, Michael R. Grunwald, Nada Hamad, Betty K. Hamilton, Yoshihiro Inamoto, Madiha Iqbal, Omer Jamy, Mark Juckett, Mohamed A. Kharfan-Dabaja, Maxwell M. Krem, Deepesh P. Lad, Jane Liesveld, Monzr M. Al Malki, Adriana K. Malone, Hemant S. Murthy, Guillermo Ortí, Sagar S. Patel, Attaphol Pawarode, Miguel-Angel Perales, Marjolein van der Poel, Olle Ringden, David A. Rizzieri, Alicia Rovó, Bipin N. Savani, Mary Lynn Savoie, Sachiko Seo, Melhem Solh, Celalettin Ustun, Leo F. Verdonck, John R. Wingard, Baldeep Wirk, Nelli Bejanyan, Richard J. Jones, Taiga Nishihori, Betul Oran, Ryotaro Nakamura, Bart Scott, Wael Saber, Vikas Gupta

Blood Adv (2024) 8 (16): 4281–4293.

https://doi.org/10.1182/bloodadvances.2024013451

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Armin Ghobadi, Javier Munoz, Jason R. Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole

Blood Adv (2024) 8 (11): 2982–2990.

https://doi.org/10.1182/bloodadvances.2023011532

Published: 2024

Includes: Supplemental data

Journal Articles

A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Blood Adv (2024) 8 (6): 1384–1391.

https://doi.org/10.1182/bloodadvances.2023011514

Published: 2024

Includes: Supplemental data

Journal Articles

Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant

Andrew Lin, Samantha Brown, Stephanie Chinapen, Yeon Joo Lee, Susan K. Seo, Doris M. Ponce, Zainab Shahid, Sergio Giralt, Genovefa A. Papanicolaou, Miguel-Angel Perales, Brian C. Shaffer

Blood Adv (2023) 7 (23): 7153–7160.

https://doi.org/10.1182/bloodadvances.2023010966

Published: 2023

Includes: Supplemental data

Journal Articles

Circulating microbial cell–free DNA is increased during neutropenia after hematopoietic stem cell transplantation

Lily M. Blair, Jamilla Akhund-Zade, Zoe A. Katsamakis, Olivia C. Smibert, Alex E. Wolfe, Paul Giardina, John Slingerland, Sivan Bercovici, Miguel-Angel Perales, Ying Taur, Marcel R. M. van den Brink, Jonathan U. Peled, Kate A. Markey

Blood Adv (2023) 7 (21): 6744–6750.

https://doi.org/10.1182/bloodadvances.2023010208

Published: 2023

Includes: Supplemental data

Journal Articles

Emergence of human CMV-induced NKG2C + NK cells is associated with CD8 + T-cell recovery after allogeneic HCT

Kattria van der Ploeg, Rosa Sottile, Theodota Kontopoulos, Brian C. Shaffer, Genovefa A. Papanicolaou, Molly A. Maloy, Christina Cho, Kevin S. Robinson, Miguel-Angel Perales, Jean-Benoît Le Luduec, Katharine C. Hsu

Blood Adv (2023) 7 (19): 5784–5798.

https://doi.org/10.1182/bloodadvances.2022008952

Published: 2023

Includes: Supplemental data

Journal Articles

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Blood Adv (2023) 7 (18): 5579–5585.

https://doi.org/10.1182/bloodadvances.2023010302

Published: 2023

Includes: Supplemental data

Journal Articles

Association between busulfan exposure and survival in patients undergoing a CD34 + selected stem cell transplantation

Blood Adv (2023) 7 (18): 5225–5233.

https://doi.org/10.1182/bloodadvances.2023009708

Published: 2023

Includes: Supplemental data

Journal Articles

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Shakthi T. Bhaskar, Vivek G. Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy I. Chen, Veronika Bachanova, Joseph E. Maakaron, Peter A. Riedell, Olalekan O. Oluwole

Blood Adv (2023) 7 (17): 4765–4772.

https://doi.org/10.1182/bloodadvances.2022008937

Published: 2023

Journal Articles

Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

Blood Adv (2023) 7 (15): 3824–3833.

https://doi.org/10.1182/bloodadvances.2022008572

Published: 2023

Journal Articles

Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma

Blood Adv (2023) 7 (14): 3501–3505.

https://doi.org/10.1182/bloodadvances.2023010003

Published: 2023

Includes: Supplemental data

Journal Articles

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanova, Loretta J. Nastoupil, Joseph P. McGuirk, Richard T. Maziarz, Olalekan O. Oluwole, Stephen J. Schuster, David L. Porter, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales

Blood Adv (2023) 7 (13): 3192–3198.

https://doi.org/10.1182/bloodadvances.2022008294

Published: 2023

Includes: Supplemental data

Journal Articles

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation

Michael Scordo, Leah J. Gilbert, Danielle M. Hanley, Jessica R. Flynn, Sean M. Devlin, Linh K. Nguyen, Josel D. Ruiz, Gunjan L. Shah, Craig S. Sauter, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Richard J. Lin, Parastoo B. Dahi, Miguel-Angel Perales, Sergio A. Giralt, Gerald A. Soff

Blood Adv (2023) 7 (8): 1536–1544.

https://doi.org/10.1182/bloodadvances.2022007838

Published: 2023

Includes: Supplemental data

Journal Articles

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults

Ioannis Politikos, Carmen Lau, Sean M. Devlin, Sean Quach, Andrew Lin, Miguel-Angel Perales, Gunjan L. Shah, Susan K. Seo, Genovefa A. Papanicolaou, Juliet N. Barker

Blood Adv (2022) 6 (24): 6291–6300.

https://doi.org/10.1182/bloodadvances.2022008047

Published: 2022

NARROW

Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis

Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes

Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant

Circulating microbial cell–free DNA is increased during neutropenia after hematopoietic stem cell transplantation

Emergence of human CMV-induced NKG2C + NK cells is associated with CD8 + T-cell recovery after allogeneic HCT

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Association between busulfan exposure and survival in patients undergoing a CD34 + selected stem cell transplantation

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only